CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 28, 2012--
Idera Pharmaceuticals, (NASDAQ: IDRA) a biotechnology company developing
Toll-like receptor candidates for the treatment of autoimmune diseases
and for use as vaccine adjuvants, today announced that members of the
management team will be presenting at the third annual “Cancer
Immunotherapy: A Long-Awaited Reality Conference” at the New York
Academy of Medicine in New York City. The presentation will be made on
Thursday, October 4, 2012 in Room 21 from 11:00 to 11:15 am.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR)
drug discovery platform to create immunomodulatory drug candidates and
has clinical development programs in autoimmune diseases. Additionally,
Idera has a collaboration with Merck & Co. for the use of TLR-targeted
candidates as vaccine adjuvants. The Company is also advancing its
gene-silencing oligonucleotide (GSO) technology for the purpose of
inhibiting the expression of disease-promoting genes. For more
information, visit http://www.iderapharma.com.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com
